Support from leading institutional investors augurs well for Imugene
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical stage immuno-oncology group, Imugene (ASX:IMU) has raised $3 million through an option plan which expired on March 31, 2017.
The price for shares exercised under the option plan was 1.5 cents per share, broadly in line with the closing price on that date. Since then the company has gone on to trade as high as 1.6 cents per share.
Although it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
Commenting on the capital raising, Chief Executive Ms Leslie Chong said, “We are pleased with the outcome of the options plan which further places Imugene in a solid position to continue the development of our HER-2 focused clinical candidate, HER-Vaxx, plus our broader mimotope platform and arginine modulator program”.
HER-Vaxx is a cancer immunotherapy designed to treat tumours that over express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. IMU is working in partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets.
Management is of the view that this partnership has the potential to create game changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies
With regard to the capital raising it was significant that the company received ongoing support from leading institutional investors Platinum Asset Management and Private Portfolio Managers, as well as Celtic Capital, all of whom have increased their investment.
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
